Bioventix (LON:BVXP) Insider Ian James Nicholson Buys 1,000 Shares

Bioventix PLC (LON:BVXP - Get Free Report) insider Ian James Nicholson bought 1,000 shares of the business's stock in a transaction on Friday, April 10th. The stock was acquired at an average cost of GBX 1,848 per share, for a total transaction of £18,480.Bioventix Stock Down 2.9%Shares of LON BVXP opened at GBX 1,836 on Monday. The firm's 50-day moving average price is GBX 1,602.29 and its two-hundred day moving average price is GBX 1,875.69. Bioventix PLC has a 52-week low of GBX 1,300 and a 52-week high of GBX 3,020. The stock has a market capitalization of £95.93 million, a P/E ratio of 13.07 and a beta of 0.48. Bioventix (LON:BVXP - Get Free Report) last announced its quarterly earnings results on Monday, March 30th. The biotechnology company reported GBX 69.38 EPS for the quarter. Bioventix had a net margin of 59.30% and a return on equity of 65.83%. The company had revenue of GBX 615.88 billion for the quarter. As a group, equities research analysts expect that Bioventix PLC will post 166.3066955 earnings per share for the current year. Bioventix Company Profile (Get Free Report)Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; and Pyrene (HOP-G) ELISA kit to monitor human exposure to industrial pollutants. It also provides contract SMAs and recombinant services. Bioventix PLC was incorporated in 2003 and is based in Farnham, United Kingdom. Recommended StoriesFive stocks we like better than BioventixThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Bioventix Right Now?Before you consider Bioventix, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bioventix wasn't on the list.While Bioventix currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here